Slingshot members are tracking this event:
FDA Designates Merck's (MRK) KEYTRUDA a Breakthrough Therapy for Treatment of Microsatellite Instability High Metastatic Colorectal Cancer
Slingshot Insights Explained
Nov 02, 2015
Don’t see a project related to the catalyst you care about?
Related Keywords Cncr, Keytruda, Metastatic Colorectal Cancer, Pd-1 Inhibitor, Microsatellite Instability High